Somavert® Efficacy and Safety in Acromegaly Patients Under Real-World Conditions Examined in Observational Study

Acromegaly is a rare hormonal disorder resulting from excessive growth hormone (GH) production, typically due to a pituitary tumor. This leads to an overproduction of insulin-like growth factor 1 (IGF-1), causing progressive disfigurement, organ enlargement, and various comorbidities like diabetes mellitus, hypertension, and cardiovascular disease. Current treatments include surgery, radiation, and somatostatin analogs, but some patients remain uncontrolled or experience significant side effects. Pegvisomant (Somavert®) is a growth hormone receptor antagonist that blocks GH action, normalizing IGF-1 levels. This study aims to understand its real-world performance.

This was an open-label, national, prospective, observational, non-interventional, multi-center, post-marketing surveillance study. The primary objective was to examine the efficacy and safety of Somavert® in patients with acromegaly under routine clinical practice. The study also aimed to assess its effects on acromegaly-related co-morbidities. The research covered articles published from January 2000 to January 2026, with an emphasis on recent studies for contemporary relevance, suggesting a review component or context for the observational data collection. Specific patient numbers, doses, routes, or durations for the observational arm are not detailed in the abstract, as it describes the study design.

The provided abstract describes the design of a post-marketing surveillance study for Somavert® but does not present any results or findings. Therefore, specific efficacy percentages, safety profiles, p-values, or changes in biomarkers are not available from this text. The study is designed to collect real-world data on Somavert®'s performance in acromegaly patients and its impact on comorbidities, but these findings are pending. No numerical data or statistical significance can be reported from this abstract.